PROC Procaps Group S.A. logo

PROC Procaps Group S.A.

Healthcare
$1.01+0.00%ClosedMarket Cap: $102.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

1.96

PEG

0.00

P/B

-108.52

P/S

0.25

EV/EBITDA

3.62

DCF Value

$10.21

FCF Yield

-17.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

58.4%

Operating Margin

12.8%

Net Margin

10.4%

ROE

-221.9%

ROA

9.2%

ROIC

12.1%

Financials

View All
PeriodRevenueNet IncomeEPS
Q3 null$118.4M$8.2M$
Q2 null$110.1M$27.0M$
Q1 null$84.2M$6.6M$
Q4 null$101.5M$10.4M$

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$10.00

Target (Median)

$10.00

Target Range

$10.00 - $10.00

0 Strong Buy0 Buy1 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
Palacios Luis Albertoofficer
SellMon Mar 30
Moreira Muniz Fernando Sebastiandirector, 10 percent owner:
SellMon Mar 30
Moreira Muniz Fernando Sebastiandirector, 10 percent owner:
SellMon Mar 30
Garcia Iragorri Carlosdirector:
SellMon Mar 30
Eguiguren Albertodirector:
SellMon Mar 30

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

LU

Exchange

Beta

0.17

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

Peers